Part of funding portal member: truCrowd, Inc.
Mobile Menu

G. Randall and Sons, Inc.

Scientific Breakthrough Hemp Product That Unlocks The Body's Own Healing Abilities

Closed on 10/30/17
Minimum target reached



funding goal 

$20k - $100k

funding goal 

Regulation CF

exemption used 

Regulation CF

exemption used 


pre money valuation 


min investment 


amount committed 



Security Type
Common Stock
$101.2 Min. Investment
$2.3 per Share
$2.3 Mil. Valuation

For each investment of $250 or greater, you will receive a 20% off coupon for purchase at



Who are we

RANDY’S REMEDY™ powered by CANNAKA™ products from G. Randall & Sons, Inc. (GR&S), currently marketed online at, contain CANNAKA, a safe, all natural, non-toxic, non-intoxicating, botanically complete hemp extract of consistent quality, offered as a nutraceutical additive that complies with all state and federal regulations. It unlocks the body’s innate healing abilities, promotes a natural inflammatory response, and supports the central nervous system.


This offering provides funds to expand GR&S’s marketing campaigns that spread the word about the scientific breakthrough and excellent products, expand distribution/sales networks to handle sales growth and underwrite R&D of new products for RANDY’S REMEDY and strategic partnerships. Investors should consider GR&S a stepping stone in today’s rapidly evolving regulatory environment to a global 21st century business. GR&S, the Strause Group, is family operated, founded by Linda, Tyler, and Brendon Strause in memory of their husband and father, George Randall Strause.


When Randy Strause was diagnosed with glioblastoma; an incurable brain cancer, he used medical marijuana but was concerned about the side effects and legal risk of THC. The need was apparent for an over-the-counter product with some of the same benefits of medical marijuana but in a safe, natural, non-toxic, non-intoxicating, consistent quality, measurable, legal, and without stigma. Currently, products containing cannabinoids are either available by prescription only, have long-term health complications, and/or struggle in the state by state medicinal marijuana (MMJ) marketplaces.

GR&S was formed to navigate and capitalize on the legal, regulatory and social changes surrounding hemp health products with a single goal from the beginning, “to create the products we wished we had when our father/husband was alive.”


GR&S has entered the multi-billion dollar Complementary and Alternative Medicine (CAM) market with the RANDY’S REMEDY powered by CANNAKA line of products:

  • Contains CANNAKA, a botanically complete hemp ingredient rich in naturally occurring cannabinoids
  • Found beneficial by customers from all walks of life dealing with a wide range of inflammatory and mood disorders
  • Supports the central nervous system
  • Works with the body to promote a healthy inflammatory response
  • Non-toxic, non-intoxicating
  • Scientifically formulated utilizing the whole plant plus terpenes
  • A scientific breakthrough that engages the endocannabinoid system (ECS), the largest system of “neuromodulators” in the body, binding to over a hundred cannabinoids to produce the documented “entourage effect,” by which the whole “plant” is greater than the sum of its parts
  • Formulated for consistent quality and potency for oral and topical products
  • Available as drops, as a soothing, deep-acting skin lotion, and as a new product, RANDY’S COMPANION for pets
  • Compliant with state and federal guidelines for sale in all 50 states
  • Pioneering development and sales of the highest quality hemp based nutraceuticals for mainstream consumption
  • Poised to be a leader in the rapidly growing CAM market
  • Scalable as the consumer public is educated to its advantages, sales grow, and new applications are introduced
  • Developing relationships in the Biopharma industries to develop IP-protected technology
Achievement & Traction

Since GR&S's inception in April 2014, we have steadily built a foundation upon which to launch a major national brand. At first, we relied on consulting contracts to sustain the company and cultivate relationships with our customers to learn more about them and our products. Today we have a solid supply chain of raw material from domestic sources and international sources as needed. We have the capabilities to expand our packaging and distribution to quickly ramp up production to 100K+ units/month and beyond as demand requires.


We have adeptly applied the limited marketing funds available to create content for social media and our customers. We consistently rate higher than the national average for click rate, open rate, and conversions. From our last bi-annual website report, we beat the national average in almost all the categories. Here is a link to that Bi-annual report.


There is genuine excitement in the marketplace for this product. We will continue our marketing effort and expand it as the business grows. Continually monitoring our metrics, we will bolster the most successful content channels. We will expand our wholesale distribution network and are implementing an affiliate marketing program. We also plan to increase sales by reaching out to health and wellness professionals and their professional organizations, small to medium size retail stores, and by forming strategic alliances with other health and dietary brands.


In an emerging market, there are few ways to estimate market size. Our first research looked at the CAM market. We worked with CR Insights, a strategic market research firm, to determine the potential market for Randy’s Remedy. While the whole CAM market is a $40B/year market and growing, we were able to identify a more targeted initial market in which Randy’s Remedy would be successful. There are over 65 million adults with the requisite disposable income in the U.S. struggling with inflammation, psoriasis, or seizures. These three conditions alone account for over $1B of the CAM marketplace. We have chosen these to focus on because the benefits are visible and the customer is able to feel the benefits quickly.

Another way to look at the potential is by analyzing the growing MMJ and adult-use marijuana markets. The market research shows how consumers are changing their minds regarding cannabinoid products. Randy's Remedy products address many of the concerns for people who are wary of these types of products. Randy's Remedy products are non-smoking, non-intoxicating, consistent, and reproducible, able to capitalize on the public’s growing acceptance of hemp products.


While keeping in mind the challenges in launching a product in this emerging industry, there are a few direct competitors selling hemp-based nutritional products. Some of these competing companies are larger in size and have financial resources greater than GR&S. However, we believe that Randy’s Remedy products are the only “botanically complete” ones currently on the market, have the highest quality, and offer many advantages over the competition (see “Solution” above). The following are five (5) such competitors that GR&S has identified:

  • Dixie Botanicals: Dixie Botanicals is an established company that delivers hemp oil products. The company sells a variety of hemp oil products with various levels of potency. Its products sell for between $22 and $420, depending on the particular product and content. 
  • Real Scientific: Real Scientific Hemp Oil is a direct competitor of GR&S. The company sells CBD-rich hemp oils of varying potency. Its products sell for between $195 and $2,250, depending on the particular product and content. 
  • BlueBird Botanicals: BlueBird Botanicals is a direct competitor of GR&S. The Company sells a variety of hemp oil products with various levels of potency. Its products sell for between $12 and $850, depending on the product and its concentration. 
  • CannaVest Corporation: CannaVest Corporation is a direct competitor of GR&S. The company develops, produces, and sells end-consumer products containing industrial hemp-based compounds with a focus on CBD. CannaVest has at least five lines of CBD-related products that it currently offers customers, ranging from hemp oil food products to beauty/health products which contain CBD. Information about the price of CannaVest Corporation's products was not available this date. 
  • HempMeds: HempMeds is a direct competitor of GR&S. The company produces and sells a variety of CBD-infused products, including hemp oil, drops and capsules, topical ointments, hair products, chewing gum, and protein bars. HempMeds' products sell for between $40 and $440, depending on the size and type of product. 
  • Other Competitors and Competitive Products: In addition, there may be other competitors, currently unknown to us, that are developing or offering hemp-based nutritional products and that are greater in size or have greater financial resources than GR&S.
  • Other products competitive with Randy’s Remedy are products under the CAM umbrella. These natural products have the same marketing and advertising regulations as Randy’s Remedy and other natural products.
Business Model

Our business model is simple. We manage our supply chain to keep costs down while delivering an exceptional product, both direct to consumer and through select retail or health professional storefront locations. 


Although we are yet to show a profit, we believe that with additional resources we will increase sales and soon cross the profit threshold and enhance the company’s valuation. We are experiencing 12% month over month increase in sales. Our margins are currently at 50% (wholesale) and 75% (direct to consumer) and we don’t expect that to change in the near future. Our objectives are to sell more product, continue utilizing the subscription model to retain our customers and make Randy’s Remedy an authority for hemp health products. 


Due to the uncertainty and growth of this market, we are also developing relationships in the Biopharma market to develop IP-protected technology. This technology may be licensed to other companies for use and/or it can be utilized in our own line of products to increase effectiveness, quality and lower costs.


The GR&S team is well suited for growth in this space. Our team includes recognized experts in the global pharmaceutical field, nutrition, and cannabis and hemp industries. Our legal and industry advisors have first-hand knowledge of the regulatory and legislative bodies and serve as industry advocates so that we are prepared to respond quickly and lobby even while regulations are being drafted.


Our team is led by The Strause Group, Linda Strause, Ph.D. and her two sons, Tyler and Brendon. Together they founded G. Randall & Sons, Inc. (GR&S), named in memory of their husband/father whose life and death from incurable brain cancer inspired their vision and defined their principles.


Dr. Linda Strause brings over 30 years’ experience and expertise in scientific rigor, clinical trial conduct, human nutrition, and higher education. Tyler Strause has over six years as a subject matter expert, covering all aspects of the plant; its cultivation, extraction, manufacturing, and chemistry. Brendon Strause has worked closely with Tyler forming Randy’s Club, a California mutual benefit non-profit, and is responsible for personnel oversight, finances, and management.


Additionally, Omar Kaczmarczyk is the Chief Marketing Officer with area expertise in crowdfunding market development and engagement. He has 40 years of experience in film and transmedia production, having consulted on over 140 international productions and movies worldwide. His experience brings immense knowledge of the worldwide transmedia marketplace. Mr. Kaczmarczyk is our lead strategist for branding, marketing, and sales in the hemp health products market.


Susan Snow is the Chief Financial Officer of GR&S. Joining the team in the beginning, she is in charge of but are not limited to identification of key partners from attorneys to bankers, assisting with the development of corporate documents, and overseeing all activities of the company pertaining to financial processes and tracking and corporate governance. Ms. Snow’s experience spans public accounting, financial services, consumer product manufacturing, construction, clean tech, and defense contracting. She has led HR, IT, Finance & Accounting, Operations, Sales & Marketing, and Contracting in her various roles. Ms. Snow has been recognized with the prestigious Director of the Year award by the Corporate Directors Forum. Ms. Snow currently serves as Chief Restructuring Officer of privately held companies where she effected successful corporate turnarounds and co-managed the restructuring in excess of $250 million in debt for her clients in the past five (5) years.


Use of Funds




You must be logged in to be able to post a question.


Business Plan Development View Download
Start-up Valuation View Download
Form C and Offering Statement View Download

Other Disclosures

Read the Form C filed with the SEC for other important disclosures, like financial statements, Directors, Officers, shareholders with more than 20% of voting rights, and more.
Use of Proceeds
The allocation of the use of proceeds among the categories of anticipated expenditures represents management’s best estimates based on the current status of the Company’s proposed operations, plans, investment objectives, capital requirements, and financial conditions. Future events, including changes in economic or competitive conditions of our business plan or the completion of less than the total Offering, may cause the Company to modify the above-described allocation of proceeds. The Company’s use of proceeds may vary significantly in the event any of the Company’s assumptions prove inaccurate. We will retain broad discretion in the allocation of the net proceeds from this Offering, reserve the right to change the allocation of net proceeds from the Offering as unanticipated events or opportunities arise and could utilize the proceeds in ways that do not necessarily improve our results of operations or enhance the value of our Common Stock. Additionally, the Company may from time to time need to raise more capital to address future needs that we may not have anticipated as of the date of this Offering Circular.
Special Note Regarding Forward-Looking Statements
This offering contains forward-looking statements within the meaning of the federal securities laws. We caution investors that any forward-looking statements presented in this offering, or which management may make orally or in writing from time to time, are based on the Company’s beliefs and assumptions made by, and information currently available to, the Company. When used, the words “anticipate,” “believe,” “expect,” “intend,” “may,” “might,” “plan,” “estimate,” “project,” “should,” “will,” “would,” “result” and similar expressions, which do not relate solely to historical matters, are intended to identify forward-looking statements. Such statements are subject to risks, uncertainties and assumptions and are not guarantees of future performance, which may be affected by known and unknown risks, trends, uncertainties and factors that are beyond the Company’s control. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, estimated or projected. While forward-looking statements reflect the Company’s good faith belief when made, they are not guarantees of future performance. The Company expressly disclaims any responsibility to update forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this offering may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. We undertake no obligation to revise or publically release the results of any revision to these forward-looking statements, except as required by law. Given these risks and uncertainties, prospective investors are cautioned not to place undue reliance on such forward-looking statements.

Back to top